Pfizer is "back on the attack" and trying to make sure the takeover of AstraZeneca is seen as being "all about science and medicine", CNBC's Catherine Boyle reports.
CNBC's Catherine Boyle outlines key events this week that will impact Pfizer's struggle to acquire U.K. rival AstraZeneca.
Pfizer kicked off the most important week to date in its struggle to gain control of U.K. rival AstraZeneca.
Pfizer has launched a fight back against critics of its proposed takeover of AstraZeneca, but did not make any fresh promises on jobs or investment.
Pfizer's $106 billion takeover approach for AstraZeneca is facing mounting scrutiny as senior U.S. politicians weigh in.
U.K. politicians from the right and the left are piling in to give their two cents on Pfizer's $106 billion bid for AstraZeneca.
The quality of the drug matters over the long period of time, says Ken Frazier, Merck CEO, talking with CNBC's Meg Tirrell about growing competition in the pharma space.
CNBC's Meg Tirrell speaks to Ken Frazier, Merck chaiman & CEO, about selling the company's consumer unit to Bayer. Frazier also gives his stance on mega-mergers and U.S corporate tax rate.
Merck has agreed to sell its consumer care unit to Bayer for $14.2 million. The "Squawk on the Street" news team discuss the $14.2 billion price tag and product development.
CNBC's Meg Tirrell reports the latest details on Bayer's deal to buy Merck's U.S. consumer care business for $14.2 billion. The brands include Claritin, Coppertone, Afrin and more.
AstraZeneca, the pharmaceutical company fighting off repeated approaches from larger rival Pfizer, has boosted its defense against the raid.
Bayer will acquire the consumer care business of U.S.-based Merck & Co for $14.2 billion in cash, the company said in a statement Tuesday.
Marijn Dekkers, Bayer CEO, shares his thoughts on imposing additional sanctions on Russia. I think it's important to sit around the table and come up with diplomatic solutions, says Dekkers.
Marijn Dekkers, Bayer CEO, discusses the details of his company's acquisition of Merck's consumer unit. Bayer can take these products and position them stronger outside the United States, says Dekkers.
The FDA approval of AstraZeneca's new heart disease drug will help it mount a defense against Pfizer's takeover bid -- but it's not really expected to be a blockbuster, CNBC's Catherine Boyle explains.
Navid Malik, head of life sciences research at Cenkos Securities, says if Pfizer is successful in acquiring Astrazeneca, it could look at some cost-cutting measures.
A decline in first-quarter profits emphasized Pfizer's need "to do a big deal", says David Williamson, Healthcare Analyst at The Motley Fool.
Pfizer reported revenues well below Wall Street expectations, hurt by falling sales of generic medicines it calls established pharmaceuticals.
Britain's opposition Labour party has called for an inquiry into a potential takeover of British firm AstraZeneca by U.S. drugmaker Pfizer.
Sean Darby, Global Head of Equity Strategy at Jefferies, describes three factors that may be contributing to the flurry of deals in the pharmaceutical sector.